Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis

Yoshiyuki Morishita1,*, Eiji Kusano2 and Daisuke Nagata1

1Division of Nephrology, Department of Medicine, Jichi Medical University, Tochigi, Japan
2Utsunomiya Social Insurance Hospital, Tochigi, Japan

Abstract: The renin-angiotensin-aldosterone system (RAAS) blockers have been widely used in chronic kidney disease patients undergoing hemodialysis; however, whether RAAS blockers have beneficial effects for cardiovascular disease in those patients has not been fully defined. This review focuses on the effects of RAAS blockers in chronic kidney disease undergoing hemodialysis for cardiovascular disease.

Keywords: Hemodialysis, clinical study, renin, angiotensin I, angiotensin II, aldosterone, angiotensin-converting enzyme inhibitor, angiotensin receptor blockers, direct renin inhibitor, cardiovascular disease.

INTRODUCTION

The cardiovascular diseases (CVD) are often complicated in chronic kidney disease undergoing hemodialysis (HD). CVD are main factor which affects the prognosis of HD patients [1-3]. Accumulated evidence suggested that antihypertensive therapy may have beneficial effects for the development of CVD in HD patients [4, 5]. The renin-angiotensin-aldosterone system (RAAS) has been reported to contribute to the hypertension, and to increase chronic inflammation and oxidative stress on vascular endothelium that may result in CVD in HD patients [6-8]. These lines of evidence suggest that RAAS blockers may have beneficial effects to prevent CVD and improve prognosis in HD patients; however, their effects have not been fully defined. This review focuses on the clinical studies of RAAS blockers in HD patients in terms of CVD.

Clinical Studies of RAAS Blockers in HD Patients

The clinical studies that investigated the effects of RAAS blockers for the CVD in HD patients are summarized in Table 1.

Angiotensin-converting Enzyme Inhibitors (ACEIs)

Angiotensin-converting enzyme inhibitors (ACEIs) block the conversion of angiotensin I (Ang I) to angiotensin II (Ang II) which leads the constriction of blood vessels, and increase blood pressure. Tradalopril and captopril have been reported to be effective for control hypertension in HD patients [9, 10]. Zheng et al. reported trandopril (2-8 mg/thrice a week) after HD session with atenolol and/or amiodipine (they were given if the patients had any member of these classes drugs as their daily regimen) significantly decrease blood pressure (from 122.2±7.1 / 75.3±10.4 mmHg to 116.4±11.6 / 70.4±11.4 mmHg) in ten HD patients [9]. Wauter et al. reported that the effect of captopril (25 to 200 mg) for hypertension in eight HD patients that showed resistant hypertension for ultrafiltration and conventional antihypertensive therapy [10]. They reported that four HD patients decreased blood pressure at normal level with captopril alone and the four remaining patients also showed significant blood pressure reduction by the combination of captopril and salt removal by replacement of 1-2 liters of ultrafilterate by an equal volume of 5% dextrose without a significant change in body weight [10]. These studies showed that ACEIs has beneficial effects for hypertension in HD patients. In addition, several studies reported that ACEIs showed cardio protective effects in HD patients as follows. The perindopril (2-4 mg after each HD session) and imidapril (2.5 mg/day) have been reported to significantly reduce left ventricular mass in HD patients compared with control group that were treated with a calcium channel antagonist or placebo respectively [11, 12]. In addition to that, this cardio protect effect by these ACEIs was suggested to be independent of blood pressure lowering effect because there was no difference in terms of the change of blood pressure between ACEIs treatment groups and control groups [11, 12].

On the other hands, there are several reports that ACEIs have no beneficial effect for CVD in HD patients. Zannad et al. reported that no beneficial effect was found in fosinopril (5-20 mg/day) for the prevention of CVD (cardiovascular death, resuscitated death, nonfatal stroke, heart failure, myocardial infarction or revascularization) in HD patients [13]. Chang et al. reported that there were no significant associations among ACEIs use and total mortality and hospitalization due to CVD in HD patients [14]. Furthermore, ACEIs use was associated with a higher risk of hospitalization due to heart failure [14]. These contradict results required further large scale clinical trials to investigate the effects of ACEIs for CVD and in HD patients.
Table 1. Clinical studies of RAAS blockers in HD patients.

| RAAS Blockers | References | Number | Duration | Intervenion | Results |
|---------------|------------|--------|----------|-------------|---------|
|               |            |        | (month)  |             |         |
|               |            |        | Treatment | Control     | Treatment | Control | CVD | CVD |
| ACEIs         | Zheng et al. | 10     | 0.5-2    | tradjopril (2-8mg/ TIW) | -5.8 / -4.9 |         |     |     |
|               | Wauterd et al. | 8      | 5        | captopril (25-200mg/ 2 day) | -45 / -29 |         |     |     |
|               | London et al. | 24     | 12       | perindopril (2-4mg/ after each HD) | nitrendipine (20-40mg/ after each HD) placebo | -27 / -15 | -20 / -10 | -70 g (LVM) | NS |
|               | Matsumoto et al. | 6      |          | imidapril (2.5mg / day) | NS | NS | -36 g (LVM) | NS |
|               | Zannad et al. | 397    | 24       | Fosinopril (5-20mg / day) | placebo + convention- al therapy | No significant benefit for fosinopril |       |     |
|               | Chang et al. | 1846   | 16-52    | ACE inhibitor +CCB, β-blocker | CCB, β-blocker | ACE inhibitor: Hazard ratio 1.41 |       |     |
| ARBs          | Saracho et al. | 406    | 6        | losartan |         | -11 / -5 |         |     |
|               | Shibasaki et al. | 24     | 30       | losartan (50mg / day) | amlodipine (5mg/day), enalapril (5mg/day) | -11 (MBP) amlodipine: -10.5% (LVMI) enalapril: -11.2% (LVMI) | -23 g/m2 (LVMI) | NS |
|               | Kannno et al. | 12     | 24       | losartan (100mg / TIW) + existing CCB, α-blocker or centrally acting agents | Placebo+ existing CCB, α-blocker or centrally acting agents | -23 g/m2 (LVMI) | NS |     |
|               | Takahashi et al. | 19     | 80       | candesartan (4-8mg / day )+ ACE in- hibitor + CCB, α-blocker or centrally acting agents | placebo+ACE inhibitor+CCB, α-blocker or centrally acting agents | NS | NS | Treatment group 16.3 % vs. control group 45.9 % |
|               | Onishi et al. | 17     | 3        | Irbesartan (50-100 mg) |         | -15.5/ -6.7 |         |     |
Table 1. Contd…..

| RAAS Blockers       | References          | Number | Duration (month) | Intervention                                                                                       | Results                                                                 |
|---------------------|---------------------|--------|------------------|-----------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
|                     |                     |        |                  |                                                                                                     |                                                                         |
| RAAS Blockers       | References          | Number | Duration (month) | Intervention                                                                                       | Results                                                                 |
|                     |                     |        |                  |                                                                                                     |                                                                         |
| Suzuki et al. (20)  | 366                 | 36     |                  | valsartan (160 mg/day), candesartan (12 mg/day) or losartan (100 mg/day) + CCB, α-blocker or centrally acting agents | △SBP/DBP: -14/-1, Control: △SBP/DBP: -16/-4, Treatment group 19% vs. control group 33% |
| ACEIs/ARBs          | Bajaj et al. (21)   | 1950   | 30               | ACEIs or ARBs                                                                                       | Primary outcome (mortality and cardiovascular events) was no significant difference among ACEIs/ARBs group (HR 0.95) and statin group (HR 1.08) compared with CCB group |
|                     |                     |        |                  |                                                                                                     |                                                                         |
| Iseki et al. (22)   | 469                 | 42     |                  | Olmesartan (10-40 mg)                                                                             | Primary outcome (mortality and cardiovascular events) was no significant difference between olmesartan group (HR 1.00) compared with no ACEI/ARB group |
|                     |                     |        |                  |                                                                                                     |                                                                         |
| Direct renin inhibitor | Morishita et al. (24) | 30       | 2                | Aliskiren (150 mg/day) + existing ACE inhibitor, ARB, CCB, α-blocker or centrally acting agents      | △SBP/DBP: -15/-5                                                       |
|                     |                     |        |                  |                                                                                                     |                                                                         |
|                     | Ishimitsu et al. (25) | 23       | 6                | Aliskiren (150mg)                                                                                   | △SBP/DBP: -8 (SBP)                                                     |
|                     | Takenaka et al. (26) | 30       | 6                | Aliskiren (150-300 mg)                                                                              | △SBP/DBP: -5 (SBP)                                                     |
| Aldosterone-resistant blocker | Gross et al. (31) | 8       | 0.5              | spironolactone (50 mg/twice daily)                                                                  | △SBP/DBP: -11 (SBP)                                                   |
|                     | Shavit et al. (32)  | 8       |                  | epilperone (25mg/twice daily)                                                                      | △SBP/DBP: -13 (SBP)                                                   |

SBP: systolic blood pressure, DBP: diastolic blood pressure, CVD: cardiovascular disease, LVM: left ventricular mass, LVMI: left ventricular mass index, NS, no significant, CCB calcium channel blocker, MBP mean blood pressure

Angiotensin Receptor Blockers (ARBs) in HD Patients

Angiotensin receptor blockers (ARBs) works to block the activation of Ang II by competitive antagonism of angiotensin II receptor type1 (AT1 receptor). Losartan has been reported to reduce blood pressure at before and after HD in hypertensive HD patients in large size clinical study [15]. Losartan reported to reduce left ventricular mass index after compared with amlodipine (calcium channel antagonist) or an enalapril (ACEI), although similar blood pressure lowering were detected in all three groups [16]. Another studies also reported that losartan (100 mg/thrice a week) reduced left ventricular hypertrophy in 24 HD patients whereas a placebo group showed no change [17]. These results suggested that this beneficial effect of losartan for cardio protection was independent of a blood pressure lowering effect. The effects of another ARBs for CVD also have been reported. Candesartan (4-8 mg/day) reduced cardiovascular events and mortality compared with placebo after in HD patients [18]. In this study, the brain natriuretic peptide (BNP) levels were significantly increased in the control group but not in
the candesartan group [18]. Irbesartan (50-100mg/day) significantly reduced blood pressure in stable maintaining HD patients [19]. Suzuki et al. reported that several ARBs (valsartan, candesartan or losartan) treatment was reduced CVD compared with no ARB treatment group for HD patients in each group during a three-year observation period [20]. There were 19% fatal or nonfatal CVD events in the ARBs group and 33% in the no ARB group [20]. Blood pressure did not differ between the ARBs group and the no ARB group. After adjustment for age, sex, diabetes, and systolic blood pressure, treatment with an ARB was independently associated with reduced fatal and nonfatal CVD events [20]. These lines of evidence demonstrated that ARBs are effective to control blood pressure and prevent CVD in HD patients. A certain level of cardio protective effects of ARBs may be independent from a blood pressure lowering effect in HD patients.

On the other hands, recently several clinical studies have been reported that ARBs have no beneficial effect for CVD and mortality in HD patients. Bajaj et al. reported that ARBs or ACEIs treatment was not associated with an overall reduction in CVD events compared with calcium channel blockers or statins treatment groups in elderly HD patients during the 2.4 years observation period [21]. Iseki et al. also reported that olmesartan treatment did not alter mortality and CVD events compared with non ACEIs and ARBs group in hypertensive HD patients during 3.5 years follow-up period [22]. These contradict results required a large size and long term clinical studies to investigate the effects of ARBs in terms of the prevention of CVD events in HD patients.

Direct Renin Inhibitor in HD Patients

An oral direct renin inhibitor; aliskiren inhibits renin activity [23]. Although renin level will increase due to negative feedback of aliskiren, Ang I, Ang II level and PRA will decrease. Little was known the effects of aliskiren in HD patients. Previously, we reported on an blood pressure lowering effect and potential CVD protective effect of aliskiren in hypertensive HD patients [24]. In that study, aliskiren significantly reduced blood pressure in HD patients [24]. In addition to that, aliskiren reduced the surrogate markers for CVD such as BNP, high-sensitivity CRP (hs-CRP), and an oxidative stress marker [24]. Isimitsu et al. also reported that aliskiren (150mg/day) significantly reduced blood pressure in maintaining HD patients [25]. Takenaka et al. reported that the aliskiren reduced morning blood pressure measured at home in HD patients with diabetic nephropathy [26]. These lines of evidence suggested that aliskiren has beneficial effects for blood pressure control in HD patients.

It should be noted that the combination of aliskiren and other class RAAS blockers should be careful because of the severe adverse effects. ALTITUDE study to investigate the effects of aliskiren added to ACEIs or ARBs in patients at high risk for CVD and with diabetes and renal impairment was suspended because more adverse effects such as stroke, renal impairment, hyperkalemia and hypotension were observed in patients who received aliskiren than in patients who received a placebo [27-29]. We also reported that when we followed up the HD patients who had been received aliskiren treatment in the previous study for 20 months, high rate (44%) of discontinuation of aliskiren owing to symptomatic hypotension was observed [30]. In that study, most patients had been received aliskiren added on their existing antihypertensives including AECIs and ARBs [30]. Taken together, the careful observation for blood pressure change is required for aliskiren treatment in hypertensive HD patients especially the combination with the other class of RAAS blockers such as ACEIs or ARBs, and further studies will be required to establish the effects of aliskiren in HD patients.

Aldosterone-receptor Blockers in HD Patients

Aldosterone-receptor blockers are receptor antagonists at the mineralocorticoid receptor. Antagonism of these receptors inhibits sodium resorption in the collecting duct of the kidney. There are a few studies to investigate the efficacy of aldosterone-receptor blocker in HD patients. Gross et al. reported spironolactone (50 mg/ twice daily) significantly reduced pre-dialysis systolic blood pressure after 2 weeks in 8 oligo-anuric HD patients [31]. Shavit et al. reported that eplerenone (20 mg/ twice daily) significantly reduced systolic blood pressure after 4 weeks by in oligo-anuric HD patients [32]. These lines of evidence suggested that beneficial effect of aldosterone-receptor blockers as antihypertensive drugs in HD patients; however, the additional large size and long term studies will be required to confirm the efficacy of aldosterone-receptor blockers in HD patients.

The Combination Therapy of RAAS Blockades in HD Patients

There are a few clinical studies to investigate the combination therapy of RAAS blockers in HD patients. Chan et al. reported that initiated on combined ACE and ARB therapy were at increased risk of CVD compared with initiated on an ARB and non-ACE after adjustment for risk factors in large size clinical study [33]. These results suggested that combination of ARB and ACEI may not have a beneficial effect on CVD in HD patients.

Adverse Effects of RAAS Blockers

ACEIs showed several adverse effects in HD patients. ACEIs may suppress erythropoiesis and induce resistance to erythropoietin [34]. Several possible mechanisms have been described: Ang II can stimulate erythropoietin cell growth and that ACEIs can inhibit this [35]. ACEIs increase plasma levels of a natural stem cell regulator which inhibits the recruitment of pluripotent haemopoietic stem cells, hence inhibit erythropoiesis [36]. ACEIs have been shown to reduce production of interleukin-12 which can stimulate erythropoiesis [37]. Occasionally, ACEIs may cause anaphylactoid reactions with AN69 dialysis membrane by increase serum bradykinin level [38-40]. Therefore it is better to avoid the combination of AN69 membranes with ACEIs in HD patients. Hyperkalemia, which is a frequent concern in HD patients, is the primary danger from RAAS blocking medications. The blockade RAAS leads to a decrease in aldosterone levels. Since aldosterone has a central role for the excretion of potassium, the RAAS blocker can cause retention of potassium. Several clinical trials of ACEIs, ARBs, a renin inhibitor and an aldosterone receptor-blocker in HD patients tracked potassium levels [13, 18, 20, 21].
24, 31]. Significant trend for increased hyperkalemia by these RAAS blockers in HD patients was not observed in these trials. Although careful and periodical monitoring of plasma potassium level is required, these results suggested that the risk of hyperkalemia by RAAS blocking in HD patients is small.

SUMMARY
RAAS blockers have been reported to have beneficial effects for blood pressure control and CVD to some extent in HD patients. However, the effects of those have not been fully established. Hence, the choice of the RAAS inhibitors in the treatment of HD patients should be carefully determined with close monitoring blood pressure. Further high-quality studies are still required to confirm the effects of RAAS blockade on CVD in HD patients.

CONFLICT OF INTEREST
None declared

ACKNOWLEDGEMENTS
None declared

ABBREVIATION

ACEIs = Angiotensin-converting enzyme inhibitors
ARBs = Angiotensin receptor blockers
AngI = angiotensin I
Ang II = angiotensin II
BNP = brain natriuretic peptide
CVD = cardiovascular disease
HD = hemodialysis
hs-CRP = high-sensitivity CRP
PRA = plasm renin activity
RAAS = renin-angiotensin-aldosterone system

REFERENCES

[1] Agarwal R, Nissenson AR, Batlle D. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 2003; 115 (4): 291-7.
[2] Collins AJ, Roberts TL; St Peter WL, Chen SC, Ebben J, Constantini E, United States Renal Data System assessment of the impact of the National Kidney Foundation-Dialysis Outcomes Quality Initiative guidelines. Am J Kidney Dis 2002; 39 (4): 784-95.
[3] Herzog CA, Ma JZ, Collins AJ. Long-term survival of dialysis patients in the United States with prosthetic heart valves: should ACC/AHA guidelines on valve selection be modified? Circulation 2002; 105 (11): 1336-41.
[4] Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension 2009; 53 (5): 860-6.
[5] Heerspink H J, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009; 373 (9668): 1009-15.
[6] Racki S, Zaputovic L, Mavric Z, et al. C-reactive protein is a strong predictor of mortality in hemodialysis patients. Ren Fail 2006; 28 (5): 427-33.
[7] Zoccali C, Benedetto FA, Mallamaci F, et al. Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients. J Hypertens 2000; 18 (9): 1207-13.
[8] Landonesser U, Drexl H. oxidative stress, the renin-angiotensin system, and atherosclerosis. Eur Heart J 2003; 5: A3-A7.
[9] Zheng S, Nath V, Coyne DW. ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients. Am J Kidney Dis 2007; 27 (5): 522-9.
[10] Wauters JP, Waebber B, Brunner HR, Guignard JP, Turini GA. Gavras H. Uncontrollable hypertension in patients on hemodialysis: long-term treatment with captopril and salt subtraction. Clin Nephrol 1981; 16 (2): 86-92.
[11] London GM, Pannier B, Guerin A P, et al. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994; 90 (6): 2786-96.
[12] Matsumoto N, Ishimitsu T, Okamura A, Seta H, Takahashi M, Matsuoka H. Effects of imidapril on left ventricular mass in chronic hemodialysis patients. Hypertens Res 2006; 29 (4): 253-60.
[13] Zannad F, Kessler M. Lebert P, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. kidney Int 2006; 70 (7): 1318-24.
[14] Chang TI, Shilane D, Brunelli SM et al. Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis. Am Heart J 2011; 162 (2): 324-30.
[15] Saracho R, Martin-Malo A, Martinez I, Aljama P, Montenegro J. Evaluation of the Losartan in Hemodialysis (ELHHE) Study. Kidney Int Suppl 1998, 68, S125-9.
[16] Shibasaki Y, Masaki H, Nishiue T, Nishikawa M, Matsubara H, Iwaski T. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 2002; 90 (3): 256-61.
[17] Kanno Y, Kaneko K, Kaneko M, et al. Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients. J Cardiovasc Pharmacol 2004; 43 (3): 380-6.
[18] Takahashi A, Takase H, Toriyama T, et al. Candesartan, an angiotensin II type 1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study. Nephrol Dial Transplant 2006; 21 (9): 2507-12.
[19] Onishi A, Morishita Y, Watanabe M, et al. Action of irbesartan on blood pressure and glucose/lipid metabolism, in hemodialysis patients with hypertension. Int J Gen Med 2013; 6: 405-11.
[20] Suzuki H, Kanno Y, Sugahara S, et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis 2008; 52 (3): 501-6.
[21] Bajaj RR, Wald R, Hackam DG, et al. Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cardiovascular outcomes in chronic dialysis patients: a population-based cohort study. Arch Intern Med 2012; 172 (7): 591-3.
[22] Iseki K, Arima H, Kohagura K, et al. Effects of angiotensin receptor blocker (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. Nephrol Dial Transplant 2013; 28: 1579-84.
[23] Rahuel J, Rasetti V, Maibaum J, et al. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol 2000; 7 (7): 493-504.
[24] Morishita Y, Hanawa S, Chinda J, Iimura O, Tsumenatsu S, Kusano E. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension. Hypertens Res 2011; 34 (3): 308-13.
[25] Ishimitsu T, Ohta S, Ohno E, et al. Long-term antihypertensive effects of aliskiren, a direct renin inhibitor, in chronic hemodialysis patients. Ther Apher Dial 2013; 17 (5): 524-31.
[26] Takenaka T, Okayama M, Kojima E, et al. Aliskiren reduces morning blood pressure in hypertensive patients with diabetic nephropathy on hemodialysis. Clin Exp Hypertens 2013; 35 (4): 244-9.
[27] Gheorghiade M, Albaghdadi M, Zannad F, et al. Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Eur J Heart Fail 2011; 13 (1): 100-6.
Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic

[28] Krum H, Massie B, Abraham WT, et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure (ATMOSPHERE) study. Eur J Heart Fail 2011; 13 (1): 107-14.

[29] Parving HH, Brenner BM, McMurray J, et al. Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 24 (5), 1663-71.

[30] Morishita Y, Watanabe M, Hanawa S, et al. Long-term effects of aliskiren on blood pressure and the renin-angiotensin-aldosterone system in hypertensive hemodialysis patients. Int J Nephrol Renovasc Dis 2012; 5: 45-51.

[31] Gross E, Rothstein M, Dombek S, Juknis HI. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis 2005; 46 (1): 94-101.

[32] Shavit L, Neykin D, Lifshitz M, Slotki I. Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients - a pilot study. Clin Nephrol 2011; 76 (5): 388-95.

[33] Chan KE, Ikizler TA, Gamboa JL, et al. Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney Int 2011; 80(9): 978-85.

[34] Macdougall IC, The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol Dial Transplant 1999; 14 (8), 1836-41.

[35] Mrug M, Stopka T, Julian BA, Prchal JF, Prchal JT. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997; 100 (9): 2310-4.

[36] Azizi M, Rousseau A, Ezan E, et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 1996; 97 (3): 839-44.

[37] Constantinescu C S, Goodman DB, Ventura ES. Captopril and lisinopril suppress production of interleukin-12 by human peripheral blood mononuclear cells. Immunol Lett 1998; 62 (1): 25-31.

[38] Verresen L, Fink E, Lemke HD, Vanreentghem Y. Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes. Kidney Int 1994; 45 (5): 1497-503.

[39] Kammerl MC, Schaefer RM, Schweda F, et al. Extracorporal therapy with AN69 membranes in combination with ACE inhibition causing severe anaphylactoid reactions: still a current problem? Clin Nephrol 2000; 53 (6): 486-8.

[40] Schaefer RM, Schaefer L, Horl WH. Anaphylactoid reactions during hemodialysis. Clin Nephrol 1994; 42 Suppl 1: S44-7.

Received: January 01, 2013
Revised: January 01, 2014
Accepted: January 05, 2014

© Morishita et al.; Licensee Bentham Open.

This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.